Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
•
General Rheumatology
•
Polymyalgia rheumatica
What would be the preferred treatment option for PMR if patient develops gastric perforation soon after initiation of steroids?
Answer from: at Community Practice
Of course Kevzara.
Sign in or Register to read more
23977
Related Questions
How would you approach management of nodular scleritis in the setting of suspected GCA?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How do you approach the work up of pulmonary artery aneurysm in the absence of other clinical features of Behcet’s?
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
Is a persistently elevated IgE level clinically relevant in a patient who has otherwise good control of EGPA and completely suppressed eosinophils on mepolizumab?
During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?
What is your approach to immunosuppression in an adult patient with biopsy-proven IgA vasculitis who has new and severe acute renal failure requiring dialysis?
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?